Nicox has announced the US launch of its rapid point-of-care diagnostic test, designed for the detection of acute conjunctivitis.
The FDA-cleared and CLIA-waived assay, AdenoPlus, uses its four-step process to detect adenovirus and provides definite results within ten minutes.
Nicox said the test, which has 90% sensitivity and 96% specificity, has been in-licensed from Rapid Pathogen Screening to commercialize AdenoPlus to eyecare professionals in the US and in other countries.
Nicox chairman and CEO Michele Garufi said with the launch of AdenoPlus, the company has taken the first step towards fulfilling its objective of starting a commercial business in the ophthalmic space.
"We have established a specialized sales team on the ground who will be marketing and selling this innovative and easy-to-use product to eyecare practitioners across the US, bringing a new, fast and accurate diagnostic option that will aid in the differential diagnosis of acute conjunctivitis," Garufi added.
"The entire management team is working tirelessly to secure additional ophthalmic assets to build a comprehensive portfolio of diagnostics, therapeutics and medical devices.
"With Bausch + Lomb's positive results observed in phase 2b with our glaucoma candidate earlier this year, solid internal R&D expertise and a growing network in the eyecare field, I believe we are in a strong position to grow rapidly as a specialist ophthalmic business."
